BW 1014
Alternative Names: BW-1014; H5N1 Influenza vaccine; Intranasal influenza virus vaccine - BlueWillow Biologics; NanoVax®-Panflu; NE-rH5 vaccineLatest Information Update: 28 Dec 2024
At a glance
- Originator NanoBio Corporation
- Developer BlueWillow Biologics
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for phase-I development in Influenza-virus-infections(Prevention) in USA (Intranasal)
- 12 Oct 2023 BlueWillow Biologics completes the phase I IN-NE-rH5 trial for Influenza virus infections (Prevention) in USA (NCT05397119)
- 29 Dec 2022 Phase I development for Influenza virus infections is ongoing in USA